Discover Roquette’s latest innovations and our new Biopharma Innovation Center!
Roquette works closely with customers in the development of innovative pharmaceutical formulations and new biopharma solutions.
With a multidisciplinary expertise and more than 50 products, Roquette offers an extended range of starches and derivatives, sugars & polyols, with an exceptional potential for meeting your needs, wherever you are, for oral dosage, nutraceuticals & OTC, Injectables, Dialysis & Specialty APIs and Biopharma.
When it comes to raw materials for cell culture or excipients in your formulation, you now have an alternative option: Manage risk with a steady supply of confidence for your materials from a source who has sole custody of the supply chain. Roquette now offers multi-compendial grade materials for both upstream and downstream applications.
To develop innovations in BioPharma and beyond, we have recently expanded our Research & Development and Customer Technical Service teams to include facilities in Singapore’s Biopolis international research and development center. Now our deep expertise in formulation and applications science enables us to provide customers with even more localized project support around the world and in-depth training on-site. Laboratory and pilot equipment at these facilities help customers address their technical and innovation challenges.
From oral dosage excipients (Rx, Gx, nutraceuticals & OTC) and biopharma materials to injectables and dialysis solutions, Roquette is holding itself to the highest industry standards - providing consistency and reliability across every ingredient.
To learn more about our latest innovations, come and visit us on our booth # 10.2 A66 and join us also for our cocktail party on Tuesday 5th at 17.00!
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...